speb/financial-data huggingface dataset:
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 65594000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 65594000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -137402000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -14149000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 43672000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Change In Payable: 41452000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Change In Receivables: 8431000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -51085000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -33623000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Common Stock: 92040000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 92040000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 4026011000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 4026011000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 0.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 25067000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 25067000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 1319906000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 205882000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Current Assets: 3038658000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 3038658000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 6594000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 6594000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Current Debt: 637173000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 637173000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 643767000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 643767000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 1561246000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 1561246000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 18036000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 18036000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Defined Pension Benefit: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Defined Pension Benefit: 0.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Depreciation: 99287000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 99287000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 99287000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 25315000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 99287000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 25315000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 92077160.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 92041905.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Diluted EPS: 3.24
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: -1.05
THEMISMED.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 298330000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -96644000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 2236000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 2236000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 4282000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — EBIT: 497144000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — EBIT: -86763000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — EBITDA: 596431000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — EBITDA: -61448000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — End Cash Position: 65594000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 3182000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 3182000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -258980000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 504444000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 504444000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Fixed Assets Revaluation Reserve: 329712000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Fixed Assets Revaluation Reserve: 329712000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 192837000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -15144000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -880000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 151070000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 3336000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 3336000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 1771024000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 1771024000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 2527633000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 2527633000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Gross Profit: 2735210000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 511134000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Interest Expense: 100395000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 24503000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 100395000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 24503000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Interest Income: 11198000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 11198000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -84923000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 11198000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Inventory: 843145000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 843145000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 4831977000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 4831977000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -121744000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 15017000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 15017000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Investmentsin Associatesat Cost: 621889000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Associatesat Cost: 621889000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Investmentsin Joint Venturesat Cost: 322598000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Joint Venturesat Cost: 322598000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 0.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 615344000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 615344000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 17325000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 17325000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 168793000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 168793000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 186118000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 186118000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 944487000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 944487000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 18650000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 18650000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 1573642000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 1573642000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Minority Interest: -14000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: -14000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Minority Interests: 2000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 1000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 0.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Net Debt: 740372000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 740372000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 7000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Net Income: 298330000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Net Income: -96644000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 298330000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -96644000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 298328000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -96645000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 298330000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -96644000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 298330000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -96644000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 396749000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 298328000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -96645000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Net Interest Income: -100395000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -24503000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 218000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -128037000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -81622000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -100395000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -24503000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Net PPE: 1745372000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 1745372000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -137442000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: -46415000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 4022675000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 4022675000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 88307000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 88307000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 18650000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 18650000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 596431000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -61448000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Normalized Income: 298330000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Normalized Income: -96644000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 347101000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Operating Income: 391195000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Operating Income: -83158000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Operating Revenue: 4055116000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 717016000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 92040120.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 92040120.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 10491000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 10491000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 54973000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 54973000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 3933921000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 3933921000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 3336000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 3336000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 84923000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 133448000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 133448000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 46695000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 15519000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 1280970000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 314468000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Other Payable: 258276000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 258276000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Other Properties: 56398000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 56398000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 124888000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 124888000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Payables: 841007000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Payables: 841007000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 18036000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 18036000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 285631000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 285631000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Pretax Income: 396749000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Pretax Income: -111266000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -154264000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 204957000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 204957000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 1319906000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 205882000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 99287000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 25315000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 34501000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 34501000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 62773000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 62773000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 2572689000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 2572689000.00
THEMISMED.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 16822000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 229834000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 380904000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Share Issued: 92040120.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 92040120.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Special Income Charges: 0.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 4026011000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 4026011000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 4022675000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 4022675000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Tax Provision: 98421000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Tax Provision: -14621000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.25
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.13
THEMISMED.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -107502000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Total Assets: 5880318000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 5880318000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 4194804000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 4194804000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Total Debt: 829885000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 829885000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 4025997000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 4025997000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Total Expenses: 3663921000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 800174000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 1854321000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 1854321000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 2841660000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 2841660000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 293075000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 293075000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 15472000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 66120000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 66120000.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Total Unusual Items: -336000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
THEMISMED.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: -336000.00
THEMISMED.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Work In Process: 133744000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 133744000.00
THEMISMED.NS balance_sheet (annual, 2025-03-31) — Working Capital: 1477412000.00
THEMISMED.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 1477412000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 578138000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 975777000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 92335065.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Basic EPS: -1.54
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 523984000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 25528000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 25528000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 92335065.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: -1.54
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -142196000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — EBIT: -115943000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — EBITDA: -90415000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 451793000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 24702000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 24702000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 1000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Net Income: -142196000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -142196000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -142197000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -142196000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -142196000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -142197000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -24702000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -24702000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -90415000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Normalized Income: -142196000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Operating Income: -126345000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 975777000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 11759000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 304119000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Pretax Income: -140645000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 523984000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 25528000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 1552000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.30
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 1102122000.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
THEMISMED.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 595107000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 779941000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 467509000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 1734278000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 15714000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 92707692.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Basic EPS: -0.39
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 92040000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 81335000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 189588000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 92040000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 3800083000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 33852000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 241455000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 2990049000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 779576000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 779576000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1739187000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 29342000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 25745000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 25745000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 92707692.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.39
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -36156000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — EBIT: -6858000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — EBITDA: 18887000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 2244000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 1720736000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 538486000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 27649000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 27649000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 764469000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 4755719000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 15714000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 176060000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 176060000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 960589000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 18650000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: -15000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Minority Interests: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 874301000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Net Income: -36156000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -36156000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -36156000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -36156000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -36156000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -36156000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -27649000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -27649000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 1720736000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 3797839000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 90988000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 18887000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Normalized Income: -36156000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Operating Income: -56621000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 779941000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 92040120.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 301714000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 71314000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 3708043000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 135621000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 32364000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 320052000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 1686884000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 108253000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Payables: 526009000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Pretax Income: -34507000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 241455000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 25745000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 92040120.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 3800083000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 3797839000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 1649000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.30
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 5824953000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 3976143000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 955636000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 3800068000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 836562000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 2024885000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 2834904000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 285698000.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 58500000.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
THEMISMED.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
THEMISMED.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 1250862000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 537509000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 901332000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 91760000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 1.10
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 291773000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 25930000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 25930000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 92601835.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 1.09
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 100936000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — EBIT: 131375000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — EBITDA: 157305000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 609559000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 27497000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 27497000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 0.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Net Income: 100936000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 100936000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 100936000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 100936000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 100936000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 100936000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -27497000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -27497000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 165958000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 109343932.46
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Operating Income: 72050000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 901332000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 12823000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 284813000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 8653000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 103878000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 291773000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 25930000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -8653000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -245067.54
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 2942000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.03
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 829282000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -8653000.00
THEMISMED.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -8653000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — +Operating Expense: 2226922000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 516168000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — +Total Revenue: 3422355000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 765305000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 508353000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 508353000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 1781166000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 1781166000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 15485000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 15485000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 92557292.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 0.96
THEMISMED.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 65594000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -48707000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 0.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 0.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 92100000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 92100000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 45381000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 45381000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 155609000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 155609000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -46020000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Change In Inventory: 32273000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -53731000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 10712000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Change In Payable: -6022000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -10142000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -20388000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -20213000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Common Stock: 92100000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 92100000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 3985838000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 3985838000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 1818000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 24721000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 24721000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 1294712000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 237500000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Current Assets: 3049769000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 3049769000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 0.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 0.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Current Debt: 782289000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 782289000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 782289000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 782289000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 1661596000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 1661596000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 33674000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 33674000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Depreciation: 103211000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 103211000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 103211000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 26008000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 103211000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 26008000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 92557292.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.96
THEMISMED.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 11439000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 88855000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 16933000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — EBIT: 126168000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — EBIT: 117594000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — EBITDA: 229379000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — EBITDA: 143602000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — End Cash Position: 45381000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 37888000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -81360000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -19836000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 717000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 1152000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 1152000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 1688720000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 1688720000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Gross Profit: 2127643000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 527805000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Interest Expense: 106886000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 27038000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 106886000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 27038000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -88937000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 2712000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Inventory: 810872000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 810872000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 4986750000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 4986750000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -25448000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 15485000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 15485000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 1818000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 0.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 0.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 218623000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 218623000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 218623000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 218623000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Long Term Equity Investment: 1084983000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 1084983000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 19358000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 19358000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Minority Interest: -16000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: -16000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Minority Interests: 2000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 1000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 1818000.00
THEMISMED.NS balance_sheet (annual, 2026-03-31) — Net Debt: 955531000.00
THEMISMED.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 955531000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 465000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Net Income: 11439000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Net Income: 88855000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 11439000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 88855000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 11437000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 88854000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 11439000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 88855000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 11439000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 88855000.00
THEMISMED.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 19282000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 11437000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 88854000.00
THEMISMED.NS income_statement (annual, 2026-03-31) — Net Interest Income: -106886000.00
THEMISMED.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -27038000.00